In CVOTs, evaluating the effects of the SGLT2 inhibitors in patients with T2D, the effect of the SGLT2 inhibitors on 3-point major adverse events (3P-MACE) was observed only in the secondary prevention group [59]; however, the CREDENCE trial demonstrated that the risk of 3P-MACE was reduced even in the primary prevention group [60]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.